Article
Source: Campus Sanofi
4 Jun 2025

Multiple Myeloma: Minimal Residual Disease

Author: Sanofi

Editorial Team

Patients with multiple myeloma who achieve minimal residual disease (MRD) negativity have been shown to have better outcomes compared with MRD positive patients¹

Achieving deeper responses can improve outcomes²

Sustained MRD– = MRD– for 1 year

MRD is the low level of malignant cells that persist even after a complete response with myeloma treatment¹

The methods used for determining MRD negativity include:

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive^6,7

Meta-analysis of 43 studies involving 8,114 patients:

Meta-analysis of 22 studies involving 4,462 patients:

MRD negativity is being considered as a regulatory surrogate endpoint for PFS^8,9

Abbreviations

References

MAT-AE-2300647-V1-Nov-23

The methods used for determining MRD negativity include:

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive6,7

MRD negativity is being considered as a regulatory surrogate endpoint for PFS8,9

Related

Achieving MRD negativity is associated with better outcomes such as longer PFS and OS compared with patients who are MRD positive^6,7

MRD negativity is being considered as a regulatory surrogate endpoint for PFS^8,9